Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091702 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
NCT00091702: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00091702 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 300 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (400% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091702, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents. This study will also determine how often and how long people who receive a vaccine are able to spread flu vaccine virus to other people.
Interventions
- BIOLOGICAL Cold-adapted live attenuated influenza vaccine (FluMist)
- BIOLOGICAL Inactivated influenza vaccine (IAIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
What the finished NCT00091702 record still lists
NCT00091702 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (400% higher).
The record links to 0 conditions, and to 2 interventions - of which Cold-adapted live attenuated influenza vaccine (FluMist) is the first listed.
NCT00091702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00091702 about?
NCT00091702 is a clinical study titled "Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents". The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents. This study will also determine how often and how long people who receive a vaccine are able to spread flu vaccine virus to other pe...
What is the current status of trial NCT00091702?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 300 participants. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00091702?
The interventions under investigation include: Cold-adapted live attenuated influenza vaccine (FluMist) (BIOLOGICAL), Inactivated influenza vaccine (IAIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00091702?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00091702's enrollment target sits among peer trials
300 124th of 2000 higher than 1,867 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics